Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox 400 mg And Miosan 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction

Next Previous
X
Search
Trial Profile

Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox 400 mg And Miosan 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclobenzaprine/etodolac (Primary) ; Cyclobenzaprine; Etodolac
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Acronyms FDCETCB-III
  • Sponsors Apsen Farmaceutica

    • Most Recent Events

    • 07 Feb 2023 Status changed from recruiting to discontinued.
    • 19 Apr 2022 Planned End Date changed from 18 Oct 2021 to 18 Dec 2022.
    • 19 Apr 2022 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top